This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

$ARIA ... this is positive news for "future" growth

? RoyalHouseOfRock (@RoyalHouseOfRock) Jun. 2 at 10:00 AM

MannKind shares rose nearly 3% ahead of the company's presentation at the Jefferies 2014 Global Health Care Conference, scheduled for today at 2:30 p.m. Investors hoped to hear positive news about Afrezza, MannKind's inhaled insulin treatment for diabetics.

$MNKD 4 hours left to the beginning of the conference.

? Donna Peran (@donnaperan) Jun. 2 at 10:20 AM

Afrezza is pending FDA-approval and was overwhelmingly recommended by an FDA subcommittee earlier this year, despite concerns about lung complications with the drug. Investors believe that the drug could take over the $45 billion diabetes-management market, as many diabetics would prefer a treatment that doesn't involve daily shots. Sentiment on the stock is 97% bullish, according to StockTwits analytics.

$MNKD added few more. Like the way she's holding. Expecting a strong action EOD

? Saif Ross (@Rossx) Jun. 2 at 10:24 AM

NPS Pharmaceuticals shares were up nearly 15% by 11 a.m. after a report in the Financial Times that Shire (SHPG) is considering acquiring the company. And investors on said shares should could climb higher than the $35.61 if rumors prove true that Shire secured a $5 billion credit facility to make a bid for the drug company, which focuses on treatments for people with rare disorders.

$NPSP (+21% pre) Shire said to have secured $5B credit facility for a takeover proposal to NPS Pharmaceuticals

? Open Outcrier (@openoutcrier) Jun. 2 at 09:09 AM

$NPSP 5B secured by Shire. Means 5B/106.33M O/S shares = $47.00 buyout price

? PR (@biotechwinner11) Jun. 2 at 07:53 AM

Pharmacyclics rose more than 2% after the company announced that its FDA-approved Imbruvica cancer drug boosted the survival rates of patients with leukemia or small lymphocytic lymphoma better than competing drugs. Patients who received the drug had a 78% reduction in the risk of cancer progression or death.

Sentiment on the stock was overwhelmingly bullish, with 89% of the crowd on StockTwits calling for gains, according to site analytics.

$PCYC This is a good stock to be in if you are not on a 1 - 2 day time horizon. Great data, FDA approved, sales ramping up.

? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:40 AM

Risk is commercialization and potential competitors. That being said, Rx up and great data show Imbruvica can compete vs. Gild/Abbv.

? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:43 AM

>>Read More: Delta Boosts Order for the Newly Stylish Airbus A321

>>Read More: How to Trade Apple Ahead of Developer Conference, Stock Split

>>Read More: Coal Shares React Positively to EPA Emissions Rules

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
ARIA $7.18 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs